YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma
Status:
Not yet recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open label, Phase 1/2 study of YH001 initially given in combination
with envafolimab, and then given in combination with envafolimab plus doxorubicin in patients
with advanced or metastatic sarcoma, followed by Phase 2 cohorts of patients with select
histologies of advanced or metastatic sarcoma.